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We have investigated the infectious entry pathway of adeno-associated virus (AAV) and recombinant AAV
vectors by assessing AAV-mediated gene transfer and by covalently conjugating fluorophores to AAV and
monitoring entry by fluorescence microscopy. We examined AAV entry in HeLa cells and in HeLa cell lines
which inducibly expressed a dominant interfering mutant of dynamin. The data demonstrate that AAV
internalizes rapidly by standard receptor-mediated endocytosis from clathrin-coated pits (half-time <10 min).
The lysosomotropic agents ammonium chloride and bafilomycin A1 prevent AAV-mediated gene transfer when
present during the first 30 min after the onset of endocytosis, indicating that AAV escapes from early
endosomes yet requires an acidic environment for penetration into the cytosol. Following release from the
endosome, AAV rapidly moves to the cell nucleus and accumulates perinuclearly beginning within 30 min after
the onset of endocytosis. We present data indicating that escape of AAV from the endosome and trafficking of
viral particles to the nucleus are unaffected by the presence of adenovirus, the primary helper virus for a
productive AAV infection. Within 2 h, viral particles could be detected within the cell nucleus, suggesting that
AAV enters the nucleus prior to uncoating. Interestingly, the majority of the intracellular virus particles
remain in a stable perinuclear compartment even though gene expression from nuclear AAV genomes can be
detected. This suggests that the process of nuclear entry is rate limiting or that AAV entry involves multiple
pathways. Nevertheless, these data establish specific points in the AAV infectious entry process and have
allowed the generation of a model for future expansion to specific cell types and AAV vector analysis in vivo.
Gene transfer vectors based on adeno-associated virus type
2 (AAV-2) show great promise for use in human gene therapy.
Several clinical trials using these reagents have recently com-
menced, and a number of patients have already been treated.
Although the clinical success of this relatively new vector sys-
tem has yet to be established, important information has been
gained from these as well as a number of earlier, preclinical
studies. While AAV can efficiently transfer genes to a number
of different cell types (muscle, brain, and liver) (36), it is ap-
parent that there are obstacles which can limit transduction of
certain cell types in vivo (2, 17, 31, 44). The further develop-
ment of AAV-based gene therapy vectors will likely benefit
from a more detailed understanding of the interactions be-
tween these vectors and target cells and the implications of
these interactions to successful gene transfer. Recently, the
cellular receptors which define the cell types potentially ame-
nable to AAV-mediated gene therapy have been described (30,
40, 41). However, the mechanisms by which AAV vectors are
taken up into cells, translocated to the nucleus, and positioned
within the cell such that their transgenes can be expressed are
still poorly understood.
Viral receptors are often involved in defining the host range
and specific tissue tropism of a virus. Recently, biochemical
and genetic evidence has been provided which suggests that
cell surface heparan sulfate proteoglycan (HSPG) serves as the
primary attachment receptor for AAV (41). Fibroblast growth
factor receptor and avb5 integrin have also been implicated as
coreceptors or facilitators of AAV entry into target cells (30,
40). However, little is known about the process of AAV infec-
tion following attachment to the cell surface. In fact, the mech-
anism of entry for most nonenveloped viruses is not well un-
derstood. Several different mechanisms have been suggested
based on morphological, ultrastructural, and biochemical stud-
ies. Direct penetration upon interaction with the plasma mem-
brane has been suggested for some nonenveloped viruses, such
as rotavirus (20), whereas other nonenveloped viruses (e.g.,
adenovirus, reovirus, poliovirus, and rhinovirus) are believed
to follow, at least initially, the same intracellular route as that
described for the enveloped viruses (25, 29, 39, 46–48). A
common paradigm for these viruses involves binding to a cell
surface receptor followed by receptor-mediated endocytosis
and endosome release. Although little is known about the
entry of AAV, a few studies of the related autonomous par-
voviruses, canine parvovirus and minute virus of mice, have
been conducted. Minute virus of mice was reported to bind to
both specialized (coated pits) and unspecified regions of the
cell membrane, and ultrastructural studies have suggested that
its internalization occurs via coated pits (24). Similarly, canine
parvovirus has been shown to be taken up into cells via small
endocytic vesicles and quickly released from these vesicles into
the cytoplasm (3, 4). The release of these viruses may take
place upon acidification of the vesicle. However, the mecha-
nism and time course of this release from the endosomal com-
partments remain unclear. Furthermore, the mechanism and
time course by which the viral particles, once released into the
cytoplasm, travel to the nucleus for expression is unknown.
The focus of this study was to evaluate the infectious entry
pathway of AAV following attachment of the virus to the cell
surface. To accomplish this, we have developed methods of
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conjugating fluorophores directly to the AAV capsid while
preserving the ability of the virus to interact with the cell in a
normal manner. Using AAV-2 and recombinant AAV-2-based
vectors as a model to interact with and transfer genes into
HeLa cells in vitro, the data presented here describe the early
steps of AAV entry into human cells. During these analyses
we observed that bound AAV particles enter the cell very rap-
idly via receptor-mediated endocytosis through clathrin-coated
pits, that release of the virus into the cytosol occurs within 30
min postinfection and requires endosomal acidification, and
that translocation of virus particles results in rapid perinuclear
accumulation followed by slower entry into the cell nucleus.
These observations begin to define a paradigm for AAV and
AAV vector entry in target cells which should impact the utility
of these reagents for human gene therapy by providing a mo-
lecular understanding of rate-limiting steps required for suc-
cessful gene transduction.
MATERIALS AND METHODS
Cell culture. HeLa and 293 cells, which have been described elsewhere (12,
14), were obtained from the American Type Culture Collection, Manassas, Va.
and maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with 10% heat-inactivated fetal bovine serum (FBS), penicillin (100 U/ml), and
streptomycin (100 mg/ml) (GIBCO, Grand Island, N.Y.) at 37°C in a 5% CO2
atmosphere. For microscopy, cells were seeded onto two-well chambered tissue
culture treated glass slides (Falcon) at a density of 104 cells per chamber or onto
four-well chambered cover glasses at a density of 5 3 103 cells per chamber and
were used 24 to 48 h later. Chambered cover glasses were coated with poly-D-
lysine (Sigma; 0.1 mg/ml; 1 h) prior to use. For confocal microscopy, HeLa S3
cells were grown in modified essential medium (S-MEM; GIBCO) containing
5% horse serum and 5% FBS.
HeLa cells expressing wild-type or the K44A mutant form of dynamin under
tetracycline-inducible control (tTA-HeLa) were kind gifts from Sandra Schmid
(Scripps Research Institute, La Jolla, Calif.) (9) and were initially maintained in
DMEM supplemented with 10% heat-inactivated FBS, 400 mg of gentamicin/ml,
200 ng of puromycin/ml, and 1 mg of tetracycline/ml. For induction of dynamin
overexpression, the cells were cultured in the absence of tetracycline for 2 days
before being exposed to AAV.
Viruses and vector production and assay. Adenovirus dl309 (19) has been
described previously. Plasmid psub201, used to generate wild-type AAV, and
plasmid pAB-11, used to generate AAVlacZ, have been described previously (13,
35). Plasmid pTRUF-5, kindly provided by Sergei Zolotukhin and Nicholas
Muzyczka (University of Florida), was used to generate AAVEGFP. Both re-
combinant AAV vectors express transgenes under the control of the cytomega-
lovirus immediate-early promoter-enhancer. AAV vectors were produced in the
absence of helper virus in 293 cells and purified either by successive bandings on
CsCl gradients (23, 38) or by heparan sulfate (HS) affinity chromatography (8,
49). Wild-type AAV was prepared in adenovirus-infected cells by transfection of
psub201 plasmid DNA as described previously (34). For preparation of fluores-
cently labeled AAV, the purity of virus was assessed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) to ensure that adenovirus and
cellular proteins had been completely removed. Preparations containing material
other than the three AAV nonstructural proteins to the limit of detection either
were further purified or were discarded because they proved unsatisfactory for
fluorescence labeling. Purified virus particles were dialyzed into 10 mM Tris–150
mM NaCl (pH 7.8) containing 10% glycerol and frozen at 280°C until required
for use. Particle numbers for wild-type AAV were determined by protein quan-
titation (7.5 mg of protein is equivalent to 1012 particles). The titer of the
recombinant virus, expressed as 293 cell transducing units, was determined by
infecting 293 cells in the presence of adenovirus (dl309) and staining for b-ga-
lactosidase activity at 36 h (37). Radiolabeled AAV was prepared by adding
[3H]methylthymidine (Amersham; 1 mCi/ml final concentration) to 293 cells 8 h
after adenovirus (dl309) and wild-type AAV infection. The infected cells were
harvested at 48 h postinfection, and the virus was purified as described above.
The activity of the labeled virus was approximately 2 3 1027 cpm per virus
particle.
Fluorescent probes. Purified virus was labeled with the carbocyanine dyes Cy2
and Cy3 (Amersham). Labeled AAV was prepared by adjusting AAV stocks to
a concentration of 1 mg/ml (1.33 3 1014 particles/ml) in sodium carbonate-
sodium bicarbonate buffer, pH 9.3. Buffer exchange was accomplished by rapid
dialysis or by gel filtration on Sephadex G-50 (Pharmacia) spin columns. One
milliliter of virus preparation was used to reconstitute the labeling reagent. After
30 min at room temperature, labeled virus was purified by extensive dialysis
against 10 mM Tris (pH 7.8)–150 mM NaCl with 10% glycerol, by gel filtration
on Sephadex G-50 using the same buffer, or by HS affinity chromatography. The
purified virus was aliquoted into single-use vials and stored at 280°C prior to use.
Labeled AAV was analyzed by SDS-PAGE to determine the specificity of the
labeling reaction and the degree of protein cross-linking. Dye concentration
was determined spectrophotometrically, using a molar extinction coefficient of
150,000 M21 cm21 at 552 nm for the Cy3 dye and an experimentally determined
molar extinction coefficient at 280 nm for purified unlabeled AAV particles.
Cy3-labeled adenovirus (Cy3Ad) was prepared as described by Leopold et al.
(22).
Virus infections. HeLa cells were infected with 1.25 3 1011 particles of Cy3-
conjugated AAV (Cy3AAV)/ml (approximately 106 particles/cell) in binding
buffer (DMEM containing 2 mM glucose, 10 mM HEPES [pH 7.3], and 1%
bovine serum albumin) at 37°C unless otherwise noted. Cells were washed three
times with binding buffer prior to infection. Lengths of viral exposure are noted
but usually consisted of a short, 10-min pulse, after which the cells were washed
twice with acid wash buffer [50 mM 2-(N-morpholino)ethanesulfonic acid
(MES)–280 mM sucrose, pH 5] and three times with binding buffer. After being
washed, the cells were either fixed immediately or maintained at 37°C during
additional incubation periods. Prior to fixation, the binding buffer was removed
and the cells were washed three times with ice-cold phosphate buffered saline
(PBS; GIBCO, Grand Island, N.Y.). Cells were fixed with 4% paraformalde-
hyde in PBS for 15 min at room temperature and washed three times with PBS.
Where indicated, cells were either treated for 5 min at room temperature with
1-mg/ml DAPI (49,69-diamidino-2-phenylindole; Molecular Probes, Inc., Eugene,
Oreg.) in PBS–0.1% Triton X-100 and washed three times with PBS or mounted
in medium containing DAPI (VECTASHIELD; Vector Laboratories, Inc., Bur-
lingame, Calif.). In some experiments, cells were treated with 25 nM ammonium
chloride or bafilomycin A1 (Sigma) as indicated.
Fluorescence microscopy. Images were collected by the use of a Leica DMIRB
microscope equipped with 403 NA 0.7 PlanApo DIC, 603 NA 1.4 PlanApo
DIC, and 1003 NA 1.4 PlanApo DIC objectives and a Hamamatsu intensified
cooled charge-coupled device camera. The 16-bit images were digitally enhanced
by subtraction of background and by gray-scale adjustment.
RESULTS
Characterization of fluorescently labeled virus. Fluores-
cently labeled AAV was generated to study the viral entry
pathway within the host cell. We characterized this reagent
extensively in order to validate wild-type AAV entry steps.
Virus labeled with cyanine-based reagents was readily visual-
ized within HeLa cells after viral infection by standard fluo-
rescence microscopy (Fig. 1). Since the fluorescent labeling of
the virus involved the covalent modification of the capsid and
exposure of virus to harsh conditions (pH 9.3), we were con-
cerned that this process might alter the biological or physical
properties of the viral particles. Although the attachment of
fluorophore led to a small amount of protein cross-linking (less
than 5%, as assessed by SDS-PAGE) (Fig. 2A), specificity for
the viral receptor (Fig. 2B), virus attachment (Fig. 1 and 2C),
and virus internalization (Fig. 1) were unchanged. Labeled
virus particles that maintained normal physical and biological
properties had dye-to-viral particle ratios in the range of 1.6 to
FIG. 1. Uptake of Cy3AAV-2 by HeLa cells. HeLa cells were incubated with
1.25 3 1011 particles of Cy3AAV-2/ml for 10 min at 37°C, washed to remove
virus particles that had not internalized, and maintained at 37°C for 30 min.
Labeled virus was visualized by fluorescence microscopy. Bar, 10 mm.
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2.3 (n 5 4). There were no detrimental effects on the physical
properties of the viral particles (Fig. 2) or significant biological
effects as evidenced by changes in viral titer (;2 3 1011 infec-
tious units/ml both prior to and following fluorescence label-
ing). However, at dye-to-particle ratios above the specified
range, e.g., .4 (n 5 2), titers were severely affected and virus
particles were prone to aggregation and precipitation. For this
reason, all studies were carried out with AAV labeled at a
dye-to-particle ratio of approximately 2. It should also be noted
that by SDS-PAGE analysis it was shown that only viral capsid
proteins were labeled with fluorophore. Fluorophore was not
seen associated with cellular proteins or with any of the non-
structural viral proteins (Fig. 2a). However, it must be stressed
that to achieve this level of specificity it was necessary to
extensively purify AAV virions. Virus was purified either on
three successive CsCl gradients or by a combination of CsCl
gradient purification and HS affinity chromatography prior to
labeling. Furthermore, all preparations were carefully moni-
tored for the presence of degraded viral proteins or cellular
proteins by SDS-PAGE to ensure specificity of the final
FIG. 2. Characterization of Cy3-labeled AAV particles: Cy3AAV-2 maintains dependence on HSPG-mediated attachment. (A) SDS-PAGE analysis of labeled
capsid proteins (lane 1) and unmodified capsid proteins (lane 2). Protein cross-linking due to the labeling reaction was less than 5%. (B) Quantitative assessment of
cell-associated Cy3 fluorescence intensity following coincubation of HeLa cells with Cy3AAV-2 and increasing amounts of heparin. (C) Assessment of cell-associated
Cy3 fluorescence by fluorescence-activated cell sorter analysis. HeLa cells were incubated with 2.5 3 1010 particles of Cy3AAV-2/ml for 30 min at 4°C (left panel) or
with 2.5 3 1010 particles of Cy3AAV-2/ml in the presence of 5 3 1012 particles of unlabeled AAV-2 (wtAAV2) for 30 min at 4°C (right panel). Both sets of cells were
then washed, fixed, and directly subjected to flow-cytometric analysis.
VOL. 74, 2000 INFECTIOUS ENTRY PATHWAY OF AAV 2779
labeled AAV preparation. The specificity and quality of the
labeled virus are demonstrated by the ability to compete cell-
associated Cy3AAV-2 fluorescence on HeLa cells with either
excess unlabeled virus (Fig. 2C) or soluble HS (Fig. 2B). These
results also demonstrate that the labeling reaction has not
altered the ability of the virus to interact with its primary
attachment receptor on the cell surface. Further evidence that
fluorescent AAV has maintained its dependence on HSPG-
mediated attachment was demonstrated by our ability to repu-
rify labeled virus via HS affinity chromatography and by the cell
binding profile of these reagents for HSPG-deficient cell lines
(41). Validation of the labeled virions as described above pro-
vided a unique reagent to assay entry mechanisms of AAV
infection.
AAV is rapidly internalized via clathrin-coated pits. Virus
internalization was monitored by using both fluorescently and
radioactively labeled AAV-2. However, the use of 3H-labeled
virus allowed easier quantification of AAV entry. HeLa cells,
which express AAV attachment receptors (HSPG) at high lev-
els, were incubated with [3H]AAV-2 at 4°C for 60 min, washed
to eliminate unattached virus, and then incubated at 37°C for
different lengths of time (0 to 90 min). Virus particles that had
not been internalized were removed from the cell surface by
washing with a mildly acidic buffer, and cell-associated radio-
activity was determined by scintillation counting. More than
60% of the bound virus particles were taken up into the cells
within the first 10 min of incubation at 37°C (Fig. 3). Thus, the
internalization half-time for AAV is less than 10 min. Al-
though this rapid entry of AAV into the host cells is indicative
of receptor-mediated endocytosis, it was of interest to deter-
mine whether productive infection by AAV requires endocy-
tosis from clathrin-coated pits. The recent identification of
host cell proteins that regulate clathrin-mediated endocytosis
provided an opportunity to more precisely define the mecha-
nism of AAV entry.
Dynamin is a 100-kDa cytosolic GTPase that selectively reg-
ulates clathrin-mediated endocytosis. Dynamin associates with
clathrin-coated membrane invaginations and has been pro-
posed to mediate the constriction of coated pits and the bud-
ding of coated vesicles from the plasma membrane (18, 43). A
dominant-negative mutant form of dynamin containing a point
mutation in the GTP binding domain (Lys-44 to Ala-44 [K44A])
has been shown to block clathrin-mediated endocytosis (9).
AAV infection of HeLa cells expressing the K44A mutant dy-
namin was measured by using the AAVlacZ vector. Uninduced
tTA-HeLa cells or cells which had been induced by removal of
tetracycline for 48 h were infected with AAVlacZ at a virus
particle-to-cell ratio of 1,000:1. The number of cells expressing
the lacZ reporter gene was then quantitated 48 h postinfection
by 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal)
histochemistry analysis. A significant decrease in AAV-medi-
ated lacZ transduction was observed in HeLa cells induced for
K44A expression (minus tetracycline) compared to that evi-
dent in tetracycline-regulated HeLa cells (Fig. 4, left panel).
The level of AAV-mediated gene delivery to HeLa cells in the
presence of tetracycline was the same as that to HeLa cells
overexpressing wild-type dynamin under the control of the
tetracycline-regulated promoter (Fig. 4, left panel). Further-
more, induction of mutant dynamin 30 min following infection
did not inhibit reporter gene expression (data not shown),
supporting the involvement of this protein in AAV entry steps
prior to gene expression. We also determined that expression
of mutant K44A dynamin, or overexpression of wild-type dy-
namin, did not interfere with virus attachment by analyzing
Cy3AAV-2 binding to tetracycline-induced and uninduced
HeLa cell lines (Fig. 4, right panel). Therefore, inhibition of
AAV-mediated gene delivery was due to decreased virus up-
take and not to inhibition of virus attachment or vector gene
expression. These findings demonstrate that the predominant
route of AAV entry into HeLa cells is via receptor-mediated
endocytosis.
AAV requires passage through an acidic compartment for
productive infection. Biochemical studies using the lysosomo-
tropic drug ammonium chloride (28) or the proton pump in-
hibitor bafilomycin A1 (6) showed that these drugs have a
significant inhibitory effect on AAV infectivity and AAV-me-
diated gene expression (Fig. 5). These drugs essentially block
infection of HeLa cells when present during the first 30 min
after the onset of endocytosis. Ammonium chloride is known
to raise the pH of intracellular organelles within 1 min follow-
ing addition (28), making it possible to inhibit a low-pH-de-
pendent endosomal escape mechanism at defined time points.
The inhibitory effect of ammonium chloride on AAV-mediated
gene transfer in HeLa cells is demonstrated in Fig. 5A. This
drug did not significantly influence AAV-mediated gene trans-
fer when present exclusively during the adsorption phase at
4°C, a temperature that blocks endocytosis, implying that the
presence of ammonium chloride at this time point did not
influence binding of AAV to the plasma membrane. We ob-
served half-maximal AAV-mediated gene expression when the
drug was added 30 min after the cells were warmed to 37°C,
suggesting that endosomal escape had already begun by this
time. This observation supports the occurrence of early endo-
some escape for AAV virions. Furthermore, AAV-mediated
gene transfer was completely resistant to ammonium chloride
by 90 min after the shift to 37°C, suggesting that penetration of
the virus into the cytosol was complete by this time.
To independently confirm the occurrence of early endosome
escape by AAV, we utilized a different drug, bafilomycin A1,
during AAV vector infection. Bafilomycin A1 is a potent in-
hibitor of the vacuolar H1-ATPase responsible for acidifica-
tion of endosomal vesicles. The influence of different bafilo-
mycin A1 concentrations on AAV infection of HeLa cells was
determined. Cells were preincubated with 0, 20, or 200 nM
bafilomycin A1 and then infected with the AAVEGFP vector.
Infection was monitored 24 h later by measuring green fluo-
rescent protein fluorescence. Both 20 and 200 nM bafilomycin
FIG. 3. Internalization of AAV-2 by HeLa cells. HeLa cells were incubated
with [3H]AAV-2 at 4°C for 60 min, washed to remove unattached virus, and then
incubated at 37°C for various lengths of time (0 to 90 min). Virus that had not
internalized was removed from the cell surface by washing with a mildly acidic
buffer, and cell-associated radioactivity was determined by scintillation counting.
Values shown are means 6 standard error and have been adjusted by subtraction
of background radioactivity (n 5 3).
2780 BARTLETT ET AL. J. VIROL.
A1 completely inhibited infection of HeLa cells by the AAV
vector (Fig. 5B). These findings support the requirement of
endosomal acidification and early endosomal escape for effi-
cient AAV vector infection.
Entry of AAV and adenovirus via distinct endosomal path-
ways. The previous data suggest that AAV is able to penetrate
the endosomal membrane fairly quickly following internaliza-
tion and that this process requires passage through an acidic
compartment. Recently, we have shown that avb5 integrin is
involved in the AAV entry process (40). It is interesting that
adenovirus, the AAV helper virus necessary for a productive
infection, also requires a slightly acidic pH and binding of the
adenovirus penton base protein to avb5 integrin in order to
efficiently escape from the endosome (7, 29, 47). Although
there is substantial evidence demonstrating that AAV ge-
nomes can be expressed in host cells in the absence of adeno-
virus, implying that AAV alone is capable of penetration into
the cytosol, it was of interest to determine synergism or com-
petition of endosomal escape following adenovirus and AAV
coinfection. Adenovirus has been shown to greatly enhance
transduction of some cells by recombinant AAV vectors due to
its effect on second-strand DNA synthesis (10, 11). By assess-
ing the fate of fluorescently labeled adenovirus and AAV, we
sought to determine whether these viruses ever colocalized
within the host cell such that adenovirus might be in a position
to physically assist AAV entry into the cytosol. HeLa cells were
coinfected with Cy2AAV-3 and Cy3Ad, and the distribution of
the viruses was monitored at 10, 20, and 40 min and at 1 h
postinfection by fluorescence microscopy. At no time point was
there significant colocalization of the AAV (green) and ade-
novirus (red) labels (Fig. 6A, top panel). In contrast, coinfec-
tion with Cy2AAV-3 and Cy3AAV-2 resulted in extensive co-
localization of the red and green signals (Fig. 6A, lower panel).
While these data do not provide direct evidence of the pres-
ence of multiple AAV particles within each endosome, they
support it. These results further support the notion that endo-
somal escape of AAV is efficient and is unaffected by ade-
novirus. Interestingly, the very early endosomes all contain
several AAV particles, as evidenced by label colocalization
(yellow signal). This may be indicative of a mechanism of
internalization requiring the grouping of multiple receptor-
AAV complexes on the surface of the host cell prior to entry.
Translocation of AAV to the nucleus. The efficiency of AAV
infection relies to a large extent on the efficient targeting of the
AAV genome to the host cell nucleus following infection. This
property is reflected in the rapid translocation of virions to the
nuclear envelope. Cy3AAV-2 was bound to HeLa cells for 2 h
at 4°C. Cells were then washed to remove unbound virus and
either fixed immediately or incubated for various periods of
time at 37°C to examine redistribution of cell-associated virus
(Fig. 6B). Prior to internalization, AAV virions were distrib-
uted evenly on the outside of the plasma membrane (Fig. 6B,
0 min). Following 30 min at 37°C, AAV exhibited a disperse,
punctate distribution in the cell, likely reflecting virions in both
endocytic compartments and free within the cytosol (Fig. 6B,
30 min). The distribution of staining had already started to
shift toward the nucleus, with some virus beginning to accu-
mulate at the nuclear envelope; however, the majority of the
virions remained widely distributed in the cytoplasm. Later
time points show a progressive perinuclear accumulation of
AAV virions (Fig. 6B, 2 h and 4 h). By 2 h following internal-
ization, nearly all of the virus particles had accumulated pe-
rinuclearly, and they remained at this location throughout the
4-h incubation period.
To more accurately access the intracellular distribution of
AAV and to determine the potential for nuclear uptake of
AAV virions, we used a laser scanning confocal microscope. In
this manner, we were able to demonstrate fluorescent AAV
particles within the nuclei of host cells within 2 h postinfection
(Fig. 7). These observations support a rapid transport of capsid
components to the nucleus with transgene expression detected
within 3 to 4 h postinfection (data not shown).
DISCUSSION
In this study, we established a number of parameters in-
volved in the early steps of AAV entry, including the use of
clathrin-coated pits, a requirement for endosome acidification,
FIG. 4. Entry of AAV-2 is mediated by dynamin-associated uptake pathways. AAV-2-mediated gene transfer (left panel) and AAV-2 attachment (right panel) to
HeLa cells overexpressing wild-type (wt) dynamin were compared to those of cells expressing mutant (K44A) dynamin. Cells were exposed to [3H]AAV-2 (1010 par-
ticles/ml) or AAVlacZ (108 particles/ml) for 2 h at 4°C, and either attachment (3HAAV-2) was measured immediately or gene transfer (AAVlacZ) was assessed 48 h
later. Expression of wild-type or mutant dynamin was induced by removal of tetracycline from the growth medium, as described in Materials and Methods. (Left panel)
AAV-2-mediated gene transfer is shown in the presence and absence of tetracycline; (right panel). AAV-2 binding is shown in the absence of tetracycline. The specificity
of AAV-2 binding was determined by competition with a 200-fold molar excess of unlabeled virus (wt AAV). Values shown are means 6 standard error (n 5 6 for each).
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escape from endosomal vesicles, and perinuclear accumulation
and nuclear translocation of virions. These data, combined
with recent studies (30, 40, 41) related to AAV receptor usage,
have allowed us to propose a model for AAV infection of
human cells (Fig. 8). AAV first binds to HSPG on the cell
surface (41) (Fig. 8A). This process may be enhanced by the
presence of fibroblast growth factor receptor (30). Following
binding, AAV is rapidly internalized by clathrin-mediated en-
docytosis (Fig. 8B) through a process that is aided by the
presence of avb5 integrin (40). Following internalization into
the early endosome, the virus encounters a weakly acidic en-
vironment which is sufficient to allow penetration into the
cytosol either from this compartment or after transport to
another, as-yet-unidentified vesicular compartment (Fig. 8C).
Following release into the cytosol, AAV accumulates perinu-
clearly (Fig. 8D) and slowly penetrates through the nuclear
pore complex (NPC) into the nucleus (Fig. 8E). The data
generated in our study provide a working template for further
confirmation of this model.
Based on the work of others which demonstrated the feasi-
bility of direct fluorophore conjugation for the labeling of
adenovirus (15, 16, 22), we sought to use a similar approach for
the labeling of AAV in order to monitor viral infection. Critical
to the success of this effort was the fact that AAV virions
labeled with the carbocyanine dyes Cy2 and Cy3 maintained all
viral functions, including binding specificity, internalization,
escape from endosomes, translocation to the nucleus, and nu-
clear entry. Previously, the use of fluorophore-conjugated
AAV to evaluate extracellular vector interactions with target
cells verified the concept of AAV-2 binding to cell surface
HSPG (1, 41) and the role of integrin avb5 in viral infection
(40). However, more importantly, in this study the use of the
fluorescent virus enabled the determination intracellular path-
ways of viral infection and additional key aspects of virus entry.
The experimental data support AAV internalization from
clathrin-coated pits by receptor-mediated endocytosis. After
attachment to the cell, the virions were rapidly cleared from
the cell surface, and after 7 to 8 min, half of the surface-bound
virions had internalized (Fig. 3). This time course of AAV
entry is very similar to that established for adenovirus. Since
adenovirus is often presented as a model nonenveloped virus
which enters cells by receptor-mediated endocytosis, our re-
FIG. 5. Inhibitory effect of ammonium chloride and bafilomycin A1 on AAV-
mediated gene transfer. (A) AAVlacZ vector was bound to HeLa cells at 4°C for
120 min, and unbound virions were washed away. Ammonium chloride (25 mM
final concentration) was added at the indicated time points (F) and was present
during different 2-h periods as indicated by the horizontal bars. The ammonium
chloride was washed out of the cells at the ends of these periods, and gene
transfer was assessed at 24 h postinfection by X-Gal histochemistry. Values
shown are means 6 standard error (n 5 3). (B) HeLa cells grown on chambered
slides were preincubated without (2) or with bafilomycin A1 (20 or 200 nM) for
30 min at 37°C. AAVEGFP vector (1010 particles/ml) was allowed to bind to the
cells for 10 min at 37°C, the cells were washed to remove unbound virus, and
vector-mediated green fluorescent protein fluorescence was assessed by fluores-
cence microscopy 24 h later. Where indicated, bafilomycin A1 was present
throughout the experiment. High-level AAV-mediated gene expression was re-
stricted to HeLa cells grown in the absence of bafilomycin A1.
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sults are in good agreement with this paradigm (29, 45–47).
Furthermore, we present for the first time a molecular view of
how these two viruses proceed through a productive coinfec-
tion (Fig. 6). Although adenovirus is typically considered to be
the primary helper virus of AAV infection, we observed, using
double labeling (Cy3Ad and Cy2AAV-3), little if any interac-
tion or cocompartmentalization of these particles after the
infection process was initiated, whereas double labeling with
two different serotypes of AAV (Cy2AAV-3 and Cy3AAV-2)
demonstrated extensive overlap (Fig. 6A), ruling out technical
concerns about the inability to observe viral Cy2 and Cy3
colocalization. In addition, these results support the premise
that the entry process for serotype 3 AAV is similar to that
established here serotype 2 AAV, and the mode of entry of the
other AAV serotypes may be similar as well, irrespective of the
primary attachment receptor (26). Studies to address this pos-
sibility are currently under way. Although numerous studies
utilizing recombinant AAV vectors for gene delivery support
AAV infection in the absence of adenovirus, these data dem-
onstrate that adenovirus and AAV traffic through the cell
separately and that adenovirus is unlikely to be in a position to
physically assist AAV entry. Therefore, all aspects of adenovi-
rus helper function must take place after viral infection and
passage of the viral particle through the cell and into the
nucleus, in agreement with earlier studies (33), and are likely
solely related to early gene expression as previously described
(10).
To examine the exact mechanism of AAV-2 internalization
into cells, we studied AAV vector-mediated gene transfer with
normal and mutant HeLa cell lines that have reduced ca-
pacity for coated-pit-mediated endocytosis (9). These mu-
tant cells overexpressed a K44A mutant form of dynamin, the
cellular protein responsible for pinching off endocytic invagi-
nations formed during endocytosis. Cells expressing the mu-
tant dynamin showed a significant decrease in AAV-mediated
gene delivery compared to uninduced cells lacking mutant
dynamin. These findings indicate that efficient AAV entry and
infection are both regulated by dynamin, an essential compo-
nent of the clathrin-coated pit endocytic pathway. We have
previously shown that entry of AAV into cells is promoted by
interaction of the virus with avb5 integrin (40). As has been
suggested for adenovirus by Wang et al. (46), av integrin clus-
tering by viral particles could facilitate localization of AAV to
coated pits that are destined for internalization. Although di-
rect evidence of this is lacking, the cytoplasmic tail of the b5
subunit of avb5 integrin contains the NPXY motif (32, 42),
which has been shown to be necessary for the localization of
certain receptors to coated pits (27). By direct visualization, we
observed clustering of AAV particles before internalization,
supporting this concept; however, further studies are needed to
determine whether specific internalization sequences in av in-
tegrins mediate AAV uptake into clathrin-coated pits.
While expression of mutant dynamin significantly inhibited
virus gene delivery, it did not completely abolish this activity.
These findings are consistent with previous reports that the
induction of mutant-dynamin expression does not completely
block internalization of transferrin, epidermal growth factor,
or adenovirus, all of which have been well documented to enter
cells via the clathrin-coated pit pathway. Residual AAV-medi-
ated gene delivery may also represent clathrin-independent
entry mechanisms such as fluid-phase pinocytosis, which are
not affected by expression of mutant dynamin (21). These
aspects of alternative pathways of viral uptake may be signifi-
cant in relation to viral vectors and target cells that are not
optimal for wild-type infection. It will be informative to exam-
FIG. 6. Pulse-labeling evaluation of fluorescent AAV distribution in HeLa cells, demonstrating the lack of intraendosomal colocalization of AAV and adenovirus
following endocytosis and time-dependent translocation of AAV from the cell membrane to the perinuclear region. (A) HeLa cells were incubated for 10 min at 37°C
with 1.25 3 1011 particles of Cy2AAV-3/ml plus either 1.25 3 1011 particles of Cy3Ad (top panel) or 1.25 3 1011 particles of Cy3AAV-2 (lower panel)/ml and assessed
for colocalization by fluorescence microscopy. Colocalization of serotype 2 and 3 AAV, but not of adenovirus and AAV, was evidenced by yellow signal from
overlapping red (Cy3) and green (Cy2) signals. Bar, 10 mm. (B) HeLa cells were incubated with 1.25 3 1011 particles of Cy3AAV-2/ml for 2 h at 4°C, washed, then
incubated at 37°C for 0, 30, 120, or 240 min and assessed by fluorescence microscopy. The positions of nuclei are evident in the 4-h panel due to DAPI (blue) staining.
Bar, 10 mm.
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ine alternative pathways of AAV uptake, both in vitro and in
vivo, in relation to the specificity of AAV vectors.
Biochemical studies using the lysosomotropic drug ammo-
nium chloride (28) or the proton pump inhibitor bafilomycin
A1 (6) showed that these drugs have a significant inhibitory
effect on AAV infectivity. These findings are compatible with
the view that penetration of AAV from the endosome into the
cytosol occurs by a low-pH-dependent mechanism. The finding
that neutralization of acidic organelles had to occur within 30
min after the initiation of endocytosis suggests that the early
endosomal population is the site of AAV penetration. This
notion is further supported by the observation that 20 nM
bafilomycin A1 is able to inhibit AAV-mediated gene delivery.
Previous studies have shown that 20 nM bafilomycin A1 has no
effect on the transport of material from early to late endo-
somes and only a modest affect on HeLa cell endosome acid-
ification (about 0.2 pH units) (5). The fact that 20 nM bafilo-
mycin A1 blocks AAV infection can be explained by the pH
threshold required for infection. From these data, it appears
that a slight elevation of the endosomal pH is sufficient to
prevent AAV infection.
The efficiency of AAV infection suggests that the AAV
capsid proteins alone are able to mediate penetration into the
cytosol. Following release of virus from the endosome, AAV is
rapidly trafficked to the host cell nucleus. Characteristic peri-
nuclear accumulation of AAV particles is evident within 40
min following the onset of endocytosis. Based on this distribu-
tion, it would appear that AAV might be retained in the peri-
nuclear recycling endosome compartment. However, our find-
ings suggest that endosomal escape is complete within this time
frame whereas perinuclear distribution of AAV virions persists
for several hours. The fact that AAV is no longer within an
endosomal compartment is consistent with the observation
that AAV particles are not degraded even after several
hours of incubation, as if they were partitioned away from
the proteases which are normally present in late endosomes
or lysosomes.
Earlier studies have suggested that AAV particles can enter
the host cell nucleus via the NPC. Since the maximal nuclear
pore size is approximately 23 nm, it is likely that translocation
of AAV (20 to 25 nm in diameter) through the NPC can take
place in the absence of uncoating or major remodeling of the
capsid structure. We have provided evidence, attained via con-
focal microscopy with Cy3-labeled virions, that AAV particles
are able to enter the nucleus, suggesting that intact virions
enter the nucleus prior to uncoating, although we cannot de-
termine from these studies if the particles are partially un-
coated or otherwise modified.
In summary, we have established specific points in the AAV
infectious entry pathway which relate to the early steps of viral
infection. Binding to a cell surface receptor initiates internal-
ization through clathrin-coated pits followed by release of the
viral particle into the cytosol and translocation to the nucleus,
where uncoating and gene expression take place. These aspects
of AAV entry can now be expanded to specific cell types and
to vector analysis in vivo. As we obtain a more detailed mo-
lecular picture of the AAV entry process, its implications in
terms of modifying AAV vectors with targeting ligands will be
significantly enhanced.FIG. 7. Distribution of Cy3AAV-2 particles in HeLa cells 2 h postinfection.
HeLa S3 cells were pulsed-labeled with 1.25 3 1011 particles of Cy3AAV-2
(red)/ml for 10 min at 37°C, washed to remove uninternalized virus, and incu-
bated at 37°C for 2 h prior to analysis by confocal microscopy. The position of the
cell nucleus was assessed by DAPI (blue) staining. A representative image is
shown, consisting of a single plane of focus through the center of a cell.
FIG. 8. Schematic representation of AAV entry and endocytic trafficking in
HeLa cells. Following binding to cell surface HSPG (A), AAV is rapidly inter-
nalized via clathrin-coated pits (B) through a process involving avb5 integrin.
Once internalized, the virus encounters a weakly acidic environment which is
sufficient to allow penetration into the cytosol (C). Following endosome release,
AAV accumulates perinuclearly (D) and slowly penetrates through the NPC into
the nucleus (E).
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